In a double-blind, placebo-controlled crossover study in eight male volunteers, toe-arm systolic gradients, measured with strain-gauge plethysmography, were measured for 4 h after 2 mg intravenous GR43175 or placebo. No changes were observed, indicating that GR43175 is without significant vasoconstrictor effect on peripheral arteries in man.
DoenickeA, BrandJ, PerrinVL. Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the treatment of severe migraine.Lancet1988; 1: 1309–11
2.
PerrinVL, FärkkiläM, GoasguenJ, DoenickeA, BrandJ, Tfelt-HansenP. Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine.Cephalalgia1989 (this volume)
3.
Tfelt-HansenP, BrandJ, DanoP, DoenickeA, FindleyLJ, IversenHK, MelchartD, SahlenderHM. Early clinical experience with subcutaneous GR-43175 in acute migraine: An overview.Cephalalgia1989 (this volume)
4.
HumphreyPPA, FeniukW, PerrenMJ, ConnorHE, OxfordAW. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175.Cephalalgia1989 (this volume)
5.
Tfelt-HansenP. The effect of ergotamine on the arterial system in man.Acta Pharmacol Toxicol1986; 59(suppl 3):1–30
6.
Tfelt-HansenP, MannichePM. Dose-response curve for the ergotamine-induced decrease of peripheral systolic blood pressure in man.Acta Pharmacol Toxicol1984; 55: 238–41
